A Phase 3 interventional study of Lurasidone HCl and Risperidone in Schizophrenia and Schizoaffective Disorder, sponsored by Sumitomo Pharma America, Inc.. Completed at 73 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-06-22.
Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing lurasidone in Schizophrenia — none open to participants now, none under way, none of them phase 3. lurasidone · Schizophrenia.
Among the 39 studies testing lurasidone in Schizophrenia, this one is the 3rd largest by enrollment, is one of 9 that started in 2008, is one of 18 in phase 3, and was the 7th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 39 studies testing lurasidone in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 9 started in 2008.
This study's enrollment of 629 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 149 across the 39 interventional studies. Of the 38 that completed or were terminated, 27 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sumitomo Pharma America, Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sumitomo Pharma America, Inc. is the lead sponsor of 181 studies on the registry; 5 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 21 (64%) have results posted.
40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 40 studies in Schizophrenia by Sumitomo Pharma Co., Ltd., this one is the 3rd largest by enrollment of the 39 interventional ones that give a count, is one of 9 that started in 2008, is one of 21 in phase 3, and was the 7th registered.
Sumitomo Pharma Co., Ltd.’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing lurasidone in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 40 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. The study will also assess the long term effectiveness of lurasidone as compared to an active comparator.
Main Inclusion Criteria:
To be eligible to enter the study, each patient must comply with the following inclusion criteria:
Main Exclusion Criteria:
To be excluded from entering this study if they fulfil any of the criteria below:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lurasidone
Drug: Lurasidone HCl
Risperidone
Drug: Risperidone
40 - 120mg per day
Risperidone
Number of Participants With Adverse Events.
Time frame: 12 months
| Milestone | Lurasidone | Risperidone |
|---|---|---|
| Started | 427 | 202 |
| Completed | 147 | 89 |
| Not completed | 280 | 113 |
| participants | Lurasidone | Risperidone |
|---|---|---|
| Number of Participants With Adverse Events. | 395 | 189 |
Collected over 14 days post-study therapy. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurasidone | — | 46/419 (11%) | 349/419 (83.3%) |
| Risperidone | — | 20/202 (9.9%) | 169/202 (83.7%) |
| Event | Lurasidone | Risperidone |
|---|---|---|
| Psychotic DisorderPsychiatric disorders | 12/419 | 8/202 |
| SchizophreniaPsychiatric disorders | 8/419 | 3/202 |
| Suicidal IdeationPsychiatric disorders | 2/419 | 2/202 |
| FallInjury, poisoning and procedural complications | 3/419 | 0/202 |
| AppendicitisInfections and infestations | 0/419 | 1/202 |
| DiverticulitisInfections and infestations | 0/419 | 1/202 |
| Urinary Tract InfectionInfections and infestations | 0/419 | 1/202 |
| Wrist FractureInjury, poisoning and procedural complications | 1/419 | 1/202 |
| AkathisiaNervous system disorders | 1/419 | 1/202 |
| DystoniaNervous system disorders | 1/419 | 1/202 |
| Event | Lurasidone | Risperidone |
|---|---|---|
| Weight IncreasedInvestigations | 39/419 | 40/202 |
| SomnolenceNervous system disorders | 57/419 | 36/202 |
| NauseaGastrointestinal disorders | 70/419 | 22/202 |
| InsomniaPsychiatric disorders | 66/419 | 27/202 |
| HeadacheNervous system disorders | 42/419 | 30/202 |
| SedationNervous system disorders | 61/419 | 28/202 |
| AkathisiaNervous system disorders | 60/419 | 16/202 |
| VomitingGastrointestinal disorders | 42/419 | 7/202 |
| AnxietyPsychiatric disorders | 38/419 | 17/202 |
| Weight DecreasedInvestigations | 31/419 | 9/202 |
| Age, Continuous(years) | Lurasidone | Risperidone | Total |
|---|---|---|---|
| Mean | 41.7 ± 11.3 | 41.6 ± 11.3 | 41.7 ± 11.3 |
| Gender(participants) | Lurasidone | Risperidone | Total |
|---|---|---|---|
| Female | 117 | 76 | 193 |
| Male | 302 | 126 | 428 |
| Region of Enrollment(participants) | Lurasidone | Risperidone | Total |
|---|---|---|---|
| United States | 279 | 133 | 412 |
| Argentina | 24 | 13 | 37 |
| Brazil | 15 | 9 | 24 |
| Thailand | 13 | 3 | 16 |
| Croatia | 7 | 5 | 12 |
| Israel | 3 | 0 | 3 |
| Chile | 19 | 7 | 26 |
| South Africa | 59 | 32 | 91 |
The record gives a start of Mar 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lurasidone
Sumitomo Pharma America, Inc. →